CIK 0001815442 · Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812992166
- Phone
- 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,158,214
- in 2 filings, $3.4M under 10b5-1 plans
Net −$4,158,214. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-11 | BAKER BROS. ADVISORS LP Director | Purchase | +1,838,621 | $86.00 | $158.1M | 7,955,916 |
| 2025-12-10 | Booth Bruce Director | Sale | −31,459 | $88.64 | $2.8M | 4,141,757 |
| 2025-12-10 | Booth Bruce Director | Sale | −17,825 | $89.25 | $1.6M | 4,123,932 |
| 2025-12-10 | Booth Bruce Director | Sale | −10,545 | $90.14 | $951K | 4,113,387 |
| 2025-12-10 | Booth Bruce Director | Sale | −47,349 | $92.41 | $4.4M | 4,066,038 |
| 2025-12-10 | Booth Bruce Director | Sale | −85,862 | $93.20 | $8.0M | 3,980,176 |
| 2025-12-10 | Booth Bruce Director | Sale | −5,979 | $88.64 | $530K | 717,267 |
| 2025-12-10 | Booth Bruce Director | Sale | −3,391 | $89.25 | $303K | 713,876 |
| 2025-12-10 | Booth Bruce Director | Sale | −2,001 | $90.14 | $180K | 711,875 |
| 2025-12-10 | Booth Bruce Director | Sale | −9,060 | $92.41 | $837K | 702,815 |
| 2025-12-10 | Booth Bruce Director | Sale | −16,338 | $93.20 | $1.5M | 686,477 |
| 2025-12-08 | Albers Jeffrey W. Director | Option exercise 10b5-1 | +5,000 | $14.18 | $71K | 5,000 |
| 2025-12-08 | Albers Jeffrey W. Director | Sale 10b5-1 | −2,748 | $89.32 | $245K | 2,252 |
| 2025-12-08 | Albers Jeffrey W. Director | Sale 10b5-1 | −2,252 | $90.30 | $203K | 0 |
| 2025-12-08 | Albers Jeffrey W. Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,000 | 7,000 | ||
| 2025-12-08 | Mainolfi Nello Chief Executive Officer | Option exercise 10b5-1 | +100,000 | $2.08 | $208K | 760,482 |
| 2025-12-08 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 | −100,000 | $89.17 | $8.9M | 660,482 |
| 2025-12-08 | Mainolfi Nello Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −100,000 | 305,559 | ||
| 2025-12-08 | Gollob Jared Chief Medical Officer | Option exercise 10b5-1 | +49,307 | $5.33 | $263K | 159,299 |
| 2025-12-08 | Gollob Jared Chief Medical Officer | Sale 10b5-1 | −13,759 | $87.37 | $1.2M | 145,540 |
Page 19 of 25 · 493 trades